![(αS)-N-[(1S)-2-[[(7S)-6,7-Dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoet…](https://static.cymitquimica.com/cas-image/thumb-webp/348824-as-n-1s-2-7s-67-dihydro-5-methyl-6-oxo-5h-dibenz-b-d-azepin-7-yl-amino-1-methyl-2-oxoethyl-35-difluoro-a-hydroxybenzeneacetamide.webp)
CAS 209984-57-6
:(αS)-N-[(1S)-2-[[(7S)-6,7-Dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluoro-α-hydroxybenzeneacetamide
Description:
The chemical substance with the name "(αS)-N-[(1S)-2-[[(7S)-6,7-Dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluoro-α-hydroxybenzeneacetamide" and CAS number "209984-57-6" is a complex organic compound characterized by its specific stereochemistry and functional groups. It features a dibenzodiazepine core, which is known for its biological activity, particularly in pharmacology. The presence of difluoro and hydroxy groups suggests potential interactions with biological targets, enhancing its solubility and reactivity. The compound's structure indicates it may exhibit properties such as enzyme inhibition or receptor modulation, making it of interest in medicinal chemistry. Its stereochemical configuration, denoted by the (αS) and (1S) designations, implies that it may have specific interactions in biological systems, which can influence its efficacy and safety profile. Overall, this compound represents a class of molecules that could be explored for therapeutic applications, particularly in areas related to neurological or psychiatric disorders.
Formula:C26H23F2N3O4
InChI:InChI=1S/C26H23F2N3O4/c1-14(29-25(34)23(32)15-11-16(27)13-17(28)12-15)24(33)30-22-20-9-4-3-7-18(20)19-8-5-6-10-21(19)31(2)26(22)35/h3-14,22-23,32H,1-2H3,(H,29,34)(H,30,33)/t14-,22-,23-/m0/s1
InChI key:InChIKey=ULSSJYNJIZWPSB-CVRXJBIPSA-N
SMILES:N(C([C@@H](NC([C@@H](O)C1=CC(F)=CC(F)=C1)=O)C)=O)[C@H]2C=3C(C=4C(N(C)C2=O)=CC=CC4)=CC=CC3
Synonyms:- (αS)-N-[(1S)-2-[[(7S)-6,7-Dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluoro-α-hydroxybenzeneacetamide
- Ly 411,575
- Ly411575
- Benzeneacetamide, N-[(1S)-2-[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluoro-α-hydroxy-, (αS)-
Filter by
Purity percentage
0
100
|
0
|
50
|
90
|
95
|
100
Found 8 products.
- Lower prices
- Higher prices
- Lower purities
- Higher purities
- Faster estimated delivery
LY-411575
CAS:Formula:C26H23F2N3O4Purity:>95.0%(HPLC)(qNMR)Color and Shape:White to Light yellow powder to crystalMolecular weight:479.48LY-411575
CAS:LY-411575, a potent γ-secretase inhibitor, is with IC50 of 0.078 nM in the membrane and 0.082 nM in cell-based. It also suppresses Notch clevage.Formula:C26H23F2N3O4Purity:97.03% - 99.38%Color and Shape:SolidMolecular weight:479.4753(S)-2-((S)-2-(3,5-Difluorophenyl)-2-hydroxyacetamido)-N-((S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl)propanamide
CAS:(S)-2-((S)-2-(3,5-Difluorophenyl)-2-hydroxyacetamido)-N-((S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl)propanamideFormula:C26H23F2N3O4Purity:98%Molecular weight:479.48LY 411575
CAS:Potent inhibitor of γ-secretase. LY 411575 inhibited production of amyloid β (Aβ) peptides with IC50 of 0.078 nM in vitro as well as decreased levels of Aβ40 and Aβ42 amyloids in brain of a mouse model for Alzheimer’s disease. In vitro studies confirmed that LY 411575 inhibited cleavage of Notch receptor at S3 site with IC50 of 0.39 nM, which blocked Notch activation and downstream signalling, leading to apoptosis in primary and immortalized Kaposi's sarcoma cells.Formula:C26H23F2N3O4Purity:Min. 95%Color and Shape:SolidMolecular weight:479.48 g/mol(S)-2-((S)-2-(3,5-Difluorophenyl)-2-hydroxyacetamido)-N-((S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl)propanamide
CAS:Purity:98%Molecular weight:479.4840088
